Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model: A Pilot Study of Patient Outcomes
Sponsor: Abramson Cancer Center at Penn Medicine
A observational or N/A phase clinical study on Genetic Predisposition to Disease and Hereditary Cancer, this trial is completed. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
May 2025 — Present [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
May 2023 — Jul 2024 [monthly]
Recruiting
-
Apr 2023 — May 2023 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Feb 2023 — Apr 2023 [monthly]
Recruiting
-
Feb 2022 — Feb 2023 [monthly]
Recruiting
-
Mar 2021 — Feb 2022 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2019 — Apr 2020 [monthly]
Recruiting
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
For direct contact, visit the study record on ClinicalTrials.gov .